News · October 30, 2026
Peptide Compounding: 6 Peptides Covered, 503A Rule Pending (Nov 2026)
HHS lets 503A pharmacies compound six peptides under ten conditions while FDA's 503A rule is pending. The dates, the status on 20 Nov 2026 and today's prices.
By Julian Caraulani · Published November 20, 2026 · Updated November 20, 2026
Key numbers
- Peptides covered
- 6: BPC-157, TB-500, MOTS-c, Semax, Epitalon, KPV
- FDA advisory panel
- Met 23 and 24 July 2026 on 7 peptides; voted in favor of the 6
- HHS policy
- Published 30 Oct 2026 (FR 2026-22192), filed 28 Oct
- Comment window
- Closed about 13 Nov 2026 (2 weeks after publication)
- 503A bulks list rule
- Pending: no proposed rule published as of 20 Nov 2026
- Next FDA panel
- Before the end of February 2027, date not set
- Announced by
- HHS, in the Federal Register (2026-22192)
What happened
On 30 October 2026, HHS published a policy saying it does not intend to take enforcement action against a state-licensed 503A pharmacy, federal facility or licensed physician compounding with six peptides: BPC-157, TB-500, MOTS-c, Semax, Epitalon and KPV. The full policy on hhs.gov sets ten conditions, including a tested ingredient from an FDA-registered maker and one peptide per product (HHS policy).
The policy follows FDA's Pharmacy Compounding Advisory Committee, which met on 23 and 24 July 2026 to discuss seven peptides for the 503A bulks list. For each of the six, HHS records that FDA's drug center (CDER) recommended against listing and the committee voted in favor. The seventh, emideltide (DSIP), was left out. FDA has not posted vote counts, so we do not print any.
Three things the policy does not do:
- It does not approve a drug. Compounded drugs are not FDA-approved, and the notice says so.
- It does not put the peptides on the 503A bulks list. The notice says "FDA's future rulemakings may propose adding some or all of these peptides" (Federal Register). That rule is the pending step.
- It is not binding. HHS may revisit it, for example if a safety signal or quality problem appears.
The HHS peptide policy guide walks through all ten conditions, and the peptide FDA status tracker shows each peptide's status in one table.
What this means for cost
For a reader, the policy means licensed telehealth programs can prescribe these peptides from a 503A pharmacy while it stands. Below is the cheapest program price we hold today for each covered peptide that a program on this site sells, with the day we read the seller's page. KPV has no priced program here yet. Compounded drugs are not FDA-approved.
| Peptide | Cheapest program today | Per month | Read |
|---|---|---|---|
| BPC-157 | HealthRX, 12-month plan | $129 | November 19, 2026 |
| TB-500 | Superpower, month-to-month plan | $149 | November 19, 2026 |
| MOTS-c | HealthRX, 12-month plan | $129 | November 19, 2026 |
| Semax | HealthRX, 12-month plan | $129 | November 19, 2026 |
| Epitalon | HealthRX, month-to-month plan | $199 | November 19, 2026 |
Lowest monthly price on the seller’s own page, on the date shown. Compare every plan on cheapest BPC-157, cheapest TB-500, cheapest MOTS-c, cheapest Semax, cheapest Epitalon.
Every program and plan is on the cost page and the cheapest list, and each program has a review with its pharmacy and plan facts. Before you pay, the compounded peptide safety guide lists what to ask a program about its pharmacy. Peptides sold as research chemicals are a different product outside this policy; research vs prescription peptides explains the difference.
What happens next
- Now
The HHS policy is in effect for the six peptides while FDA rulemaking is pending. The comment window on the docket (HHS-OASH-2026-0496) closed about 13 November 2026.
- Not scheduled
A proposed FDA rule adding some or all of the six to the 503A bulks list. None has been published in the Federal Register as of 20 November 2026; we will date it here when it appears.
- Before end of Feb 2027
FDA's next compounding committee meeting, on LL-37, GHK-Cu, Dihexa acetate, Melanotan II and PEG-MGF. FDA has not set the date.
- Until a final rule
The policy runs for each peptide until FDA addresses it in a final rule, unless HHS revisits it sooner.
Sources
- Federal Register 2026-22192: HHS enforcement discretion policy for certain peptide bulk drug substances, read November 20, 2026
- HHS: full policy with Appendices A and B (PDF), read November 18, 2026
- FDA: Pharmacy Compounding Advisory Committee, 23 and 24 July 2026 meeting page, read November 20, 2026
- FDA: upcoming Pharmacy Compounding Advisory Committee meeting, read November 20, 2026
- Federal Register search: 503A bulk drug substances (no proposed peptide rule as of 20 Nov 2026), read November 20, 2026